Since the Valsartan scandal in June 2018, there has been a growing interest in the risk assessment of potential traces of toxic nitrosamines in drug substances and products. The Official Medicines Control Laboratories (OMCLs) of the General European OMCL Network (GEON) were involved in investigations and actions to address the issues related to the detection of N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA) and other relevant nitrosamines. The EMA gives manufacturers six months to complete risk based testing, and three years for all further necessary tests and implementation of the corresponding changes in the manufacturing license.

Based on a CVUA Karlsruhe method, DSI-pharm recently implemented a generic LC-MS/MS method with limits of quantification (LOQ) between 1 ng/mL and 5 ng/mL for 6 different nitrosamines including NDMA and NDEA (current spectrum of nitrosamines contained see Table and Figure 1). Samples of drug substances and products are tested for nitrosamine traces after being diluted in a solvent using liquid chromatography. This is coupled with mass spectrometry using atmospheric pressure chemical ionization (UHPLC-APCI-MS/MS) in multiple reaction monitoring mode (MRM).

The generic LC-MS/MS method can be easily adapted to different drug substances and products if necessary. The method must then be validated under GMP for each product. The final LOQ´s will range between about 0,010 ppm and 0,050 ppm depending on the nitrosamines and the required sample dilution. Upon request, further nitrosamines of interest can be implemented into the method.

DSI-pharm is highly experienced in trace and residue testing in food and pharma products and can offer you attractive turnaround times – also for method development and validation.

Do you have further questions about the analysis of nitrosamines?

Please contact our expert Dr. Serap Acikgöz.

 

Über die Tentamus Group GmbH

Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China, Japan, India and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food & feed, pharmaceuticals & medical, agrosciences, cosmetics, agriculture & environment and nutraceutical & supplements). Tentamus Group is represented in over 65 locations worldwide. More than 2,500 highly-trained staff members work in over 2.5 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.

Tentamus Group
An der Industriebahn 5
13088 Berlin, Germany
www.tentamus.com

Firmenkontakt und Herausgeber der Meldung:

Tentamus Group GmbH
An der Industriebahn 26
13088 Berlin
Telefon: +49 (30) 206038-230
Telefax: +49 (30) 206038-190
http://www.tentamus.com

Ansprechpartner:
Serap Acikgöz
General Manager Pharma; DSI-pharm
Telefon: +49 441 3613265 449
E-Mail: serap.acikgoez@tentamus.com
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel